A Phase I/II Study of DYP688 for People with Advanced Uveal Melanoma and Other Melanomas with GNAQ/11 Gene Mutations
Source: Memorial Sloan Kettering Cancer Centre , November 2022
Full Title
A Phase I/II, Multi-Center, Open Label Study of DYP688 in Patients with Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
Purpose
The purpose of this study is to find the highest dose of the investigational drug DYP688 that can be given safely in people with metastatic uveal melanoma, mucosal melanoma, or skin melanoma that contains mutations in the GNAQ or GNA11 genes. These mutated genes make proteins called GPCR that cause melanoma cells to grow and spread.
DYP688 attaches to a protein on the surface of melanoma cells and brings an anticancer drug inside the cells to block the action of GPCR, causing the cancer cells to die. It is given intravenously (by vein).